Pregabalin: Mechanism, Indications, Dosing, and Adverse Effects
Pregabalin is a calcium channel α2-δ ligand that binds to voltage-gated calcium channels to inhibit neurotransmitter release, providing effective treatment for neuropathic pain conditions and partial-onset seizures, with predictable linear pharmacokinetics that allow straightforward dosing starting at 150 mg/day. 1
Mechanism of Action
Pregabalin binds with high affinity to the α2-δ subunit of voltage-gated calcium channels in the central nervous system 2. This binding reduces depolarization-induced calcium influx, which subsequently decreases the synaptic release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P 2, 3. Importantly, pregabalin has no demonstrated effects on GABAergic mechanisms 3, distinguishing it from many other antiepileptic drugs.
Clinical Indications
First-Line Neuropathic Pain Conditions
Pregabalin is recommended as first-line therapy for several neuropathic pain conditions 1:
- Postherpetic neuralgia (PHN): 62% of patients achieve ≥30% pain reduction with 600 mg/day versus 24% with placebo (NNTB 2.7) 4
- Painful diabetic peripheral neuropathy (DPN): 47% achieve ≥30% pain reduction with 300 mg/day versus 42% with placebo 4
- Mixed or post-traumatic neuropathic pain: 48% achieve ≥30% pain reduction with 600 mg/day versus 36% with placebo 4
- Central neuropathic pain: 44% achieve ≥30% pain reduction with 600 mg/day versus 28% with placebo 4
Epilepsy
- Adjunctive therapy for partial-onset seizures in adults and children ≥1 month of age 5
- In pediatric patients 4-17 years: 10 mg/kg/day provides 21% greater seizure reduction versus placebo 5
Other FDA-Approved Indications
Note: Pregabalin shows no evidence of benefit in HIV neuropathy 4.
Dosing Regimen
Neuropathic Pain
Starting dose: 50 mg three times daily or 75 mg twice daily 1
Titration schedule:
- Increase to 300 mg/day after 3-7 days
- Then increase by 150 mg/day every 3-7 days as tolerated 1
Maximum dose: 600 mg/day (200 mg three times daily or 300 mg twice daily) 1
Duration of adequate trial: 4 weeks 1
Key advantage over gabapentin: Pregabalin has linear pharmacokinetics, making dosing more straightforward. Most patients can start at 150 mg/day in 2-3 divided doses, which has been found efficacious in some trials 1. Higher doses (600 mg/day) are not consistently more effective than 300 mg/day and carry greater adverse effect rates 1.
Partial-Onset Seizures
Pediatric patients (4 to <17 years):
- Starting: 2.5 mg/kg/day
- Effective dose: 10 mg/kg/day (maximum 600 mg/day) 5
Pediatric patients (1 month to <4 years):
- Effective dose: 14 mg/kg/day 5
Critical Dosing Considerations
Renal insufficiency: Dose reduction required; adjust based on creatinine clearance 1
Geriatric patients: Consider lower starting doses and slower titration 1
Food: No clinically relevant effect on absorption; can be taken without regard to meals 3
Pharmacokinetic Profile
Pregabalin demonstrates highly predictable pharmacokinetics 3:
- Absorption: Extensive, rapid, proportional to dose
- Time to peak: ~1 hour
- Steady state: 24-48 hours
- Bioavailability: High (>90%)
- Half-life: 6.3 hours
- Protein binding: None
- Metabolism: <2%; excreted virtually unchanged by kidneys
- Drug interactions: No hepatic metabolism; does not induce or inhibit cytochrome P450 enzymes, making pharmacokinetic drug-drug interactions unlikely 3
Common Adverse Effects
Most Frequent (Dose-Dependent)
Dizziness and somnolence are the most common adverse effects, which can be reduced by starting with lower doses and titrating cautiously 1:
At 300 mg/day:
At 600 mg/day:
Other Common Adverse Effects (≥5%)
- Peripheral edema: 9-12% at 300-600 mg/day 5
- Weight gain: 4-16% (dose-dependent) 5
- Blurred vision: 4-12% 5
- Dry mouth: 4-6% 5
- Ataxia: 3-20% 5
- Confusion: 2-7% 5
- Thinking abnormal (difficulty with concentration/attention): 2-9% 5
Serious Adverse Events
Serious adverse events occur at similar rates to placebo: 3.1% with pregabalin 300 mg versus 2.6% placebo; 3.4% with 600 mg versus 3.4% placebo 4.
Rare but Serious Adverse Effects
- Angioedema and hypersensitivity reactions 5
- Respiratory depression (particularly with concomitant CNS depressants) 5
- Myoclonus (rare; can occur even without renal dysfunction) 6
- Suicidal behavior and ideation 5
Misuse and Dependence
Pregabalin is a Schedule V controlled substance in the United States 1. Recent pharmacovigilance data identified signals of misuse, dependence, drug diversion, and prescription tampering 7. Caution is warranted in patients with a history of substance abuse 8.
Critical Clinical Pitfalls
Discontinuation
Do not discontinue pregabalin abruptly. Taper when discontinuing to avoid withdrawal syndrome 5. Abrupt discontinuation increases risk of adverse reactions including seizures in epilepsy patients 5.
Renal Function
Always assess renal function before prescribing. Pregabalin is eliminated unchanged by the kidneys, requiring dose adjustment in renal insufficiency 1.
Driving and Operating Machinery
Impaired driving ability has been reported (710 cases in global pharmacovigilance data) 7. Counsel patients about potential CNS effects before engaging in hazardous activities.
Conditions Requiring Caution
- Nerve compression syndromes (e.g., carpal tunnel syndrome): Use cautiously 8
- History of substance abuse: Increased risk of misuse 8
- Concomitant CNS depressants: Increased risk of respiratory depression 5
- Cardiac disease: Monitor for peripheral edema 5